Turn Therapeutics Inc. (TTRX)
| Market Cap | 108.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.19M |
| Shares Out | 29.79M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,749 |
| Open | 3.670 |
| Previous Close | 3.700 |
| Day's Range | 3.600 - 3.690 |
| 52-Week Range | 2.570 - 26.500 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 8.00 (+120.39%) |
| Earnings Date | May 14, 2026 |
About TTRX
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Tu... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for TTRX stock is "Strong Buy" and the 12-month stock price target is $8.0.
News
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today...
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered int...
Turn Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
A novel polymer-based ointment with a unique IL-36/IL-31 inhibition mechanism is advancing through a phase II eczema trial, with interim and top-line data expected in Q2 2026. The company is also pursuing onychomycosis and other dermatology indications, supported by strong IP and a low burn rate.
Turn Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company is advancing a novel topical therapy for moderate to severe eczema, with a large phase II trial underway and interim results expected in Q2 2026. Its lead asset, GX-03, shows strong safety and efficacy, with plans for phase III trials in both eczema and onychomycosis.
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, toda...
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced t...
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectiou...
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, ...
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, d...
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
Conversation Centered Around Healthcare Communications and Pandemic Preparedness Conversation Centered Around Healthcare Communications and Pandemic Preparedness
Turn Therapeutics' GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, ...
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, ...
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, w...
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy Company to host shareholder webinar today, October 22...
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders a...
Turn Therapeutics Appoints Arthur Golden to Board of Directors
Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs Veteran corporate advisor to strengthen governance, oversight, and st...
Turn Therapeutics Announces Expected First Day of Trading on NASDAQ Global Market
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing dermatology, wound care, and anti-infective therapies, today a...